(Total Views: 151)
Posted On: 12/09/2021 7:11:31 AM
Post# of 7
IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?
$FENC
Fennec Pharmaceuticals (NASDAQ:FENC), a "specialty pharmaceutical company", received a CRL from the FDA for its New Drug Application (NDA) for PEDMARK™ (sodium thiosulfate), citing deficiencies in manufacturing.
This marks the second CRL for the Company. which earlier served a CRL for deficiencies in manufacturing in August 2020. Can Fennec Pharmaceuticals successfully address the concerns and obtain an approval for Pedmark?
Read on to find out more!
https://www.aviseanalytics.com/is-third-time-...ceuticals/
$FENC
Fennec Pharmaceuticals (NASDAQ:FENC), a "specialty pharmaceutical company", received a CRL from the FDA for its New Drug Application (NDA) for PEDMARK™ (sodium thiosulfate), citing deficiencies in manufacturing.
This marks the second CRL for the Company. which earlier served a CRL for deficiencies in manufacturing in August 2020. Can Fennec Pharmaceuticals successfully address the concerns and obtain an approval for Pedmark?
Read on to find out more!
https://www.aviseanalytics.com/is-third-time-...ceuticals/
(0)
(0)
